FA
ABCL icon

Fedenia Advisers’s AbCellera Biologics ABCL Stock Holding History

Fedenia Advisers’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Buy
+40,000
New +$196K 0.07% 101

Other funds holding ABCL

CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $3.04B AUM 94.11% 1-Year Est. Return
HOWA
Heritage Oak Wealth Advisors Santa Rosa Beach, Florida $340M AUM 29.73% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
NA
Networth Advisors Canonsburg, Pennsylvania $172M AUM
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

Fedenia Advisers's ABCL Position: Q2 2026 in Review

Fedenia Advisers opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 40,000 shares worth $314K. The stake represents 0.07% of the portfolio and ranks #101 among its holdings.

19 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Fedenia Advisers held 40,000 shares of AbCellera Biologics worth $314K as of Q2 2026.
  • AbCellera Biologics was a new Fedenia Advisers position in Q2 2026.
  • AbCellera Biologics made up 0.07% of Fedenia Advisers's portfolio in Q2 2026, its #101 holding.
  • 19 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Fedenia Advisers's 13F filing for Q2 2026, filed 22 Jul 2026.